Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 15, 2022

SELL
$1.63 - $3.43 $32,168 - $67,691
-19,735 Closed
0 $0
Q3 2021

Jun 21, 2023

BUY
$3.19 - $5.48 $62,954 - $108,147
19,735 New
19,735 $64,000
Q3 2021

Mar 30, 2023

BUY
$3.19 - $5.48 $11,694 - $20,089
3,666 Added 22.81%
19,735 $64,000
Q3 2021

Nov 15, 2021

BUY
$3.19 - $5.48 $11,694 - $20,089
3,666 Added 22.81%
19,735 $64,000
Q2 2021

Jun 21, 2023

BUY
$4.78 - $6.84 $76,809 - $109,911
16,069 New
16,069 $90,000
Q2 2021

Mar 30, 2023

SELL
$4.78 - $6.84 $38,641 - $55,294
-8,084 Reduced 33.47%
16,069 $90,000
Q2 2021

Aug 16, 2021

BUY
$4.78 - $6.84 $76,695 - $109,747
16,045 Added 66854.17%
16,069 $90,000
Q1 2021

Jun 26, 2023

BUY
$5.9 - $9.13 $142,502 - $220,516
24,153 New
24,153 $163 Million
Q1 2021

Mar 30, 2023

BUY
$5.9 - $9.13 $9,900 - $15,320
1,678 Added 7.47%
24,153 $163,000
Q1 2021

May 14, 2021

SELL
$5.9 - $9.13 $132,460 - $204,977
-22,451 Reduced 99.89%
24 $163,000
Q4 2020

Jun 22, 2023

BUY
$3.0 - $6.71 $67,425 - $150,807
22,475 New
22,475 $150,000
Q4 2020

Mar 30, 2023

BUY
$3.0 - $6.71 $2,787 - $6,233
929 Added 4.31%
22,475 $150,000
Q4 2020

Feb 16, 2021

BUY
$3.0 - $6.71 $2,787 - $6,233
929 Added 4.31%
22,475 $151,000
Q3 2020

Jun 26, 2023

BUY
$2.54 - $4.56 $54,726 - $98,249
21,546 New
21,546 $66,000
Q3 2020

Mar 30, 2023

BUY
$2.54 - $4.56 $12,372 - $22,211
4,871 Added 29.21%
21,546 $66,000
Q3 2020

Nov 13, 2020

BUY
$2.54 - $4.56 $12,372 - $22,211
4,871 Added 29.21%
21,546 $66,000
Q2 2020

Jun 26, 2023

BUY
$0.78 - $5.25 $13,006 - $87,543
16,675 New
16,675 $64,000
Q2 2020

Mar 30, 2023

BUY
$0.78 - $5.25 $13,006 - $87,543
16,675 New
16,675 $64,000
Q2 2020

Aug 14, 2020

BUY
$0.78 - $5.25 $13,006 - $87,543
16,675 New
16,675 $64,000

Others Institutions Holding AWH

About Aspira Women's Health Inc.


  • Ticker AWH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 124,296,000
  • Market Cap $123M
  • Description
  • Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gyneco...
More about AWH
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.